

## Retifanlimab (ZYNZY) Criteria for Use December 2024

**VA Pharmacy Benefits Management Services and National Formulary Committee**

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

### Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive retifanlimab.

- Autoimmune disease
- Immunosuppression including corticosteroid equivalent to >10mg per day of prednisone
- Primary immunodeficiency
- History of allogeneic hematopoietic stem cell transplant or solid organ transplant
- Pregnancy
- Lactating

### Inclusion Criteria

One of the following criteria must be met:

- Indication is FDA approved
- Off-label use supported by high-level published data

### Additional Inclusion Criteria

All of the following criteria must be met:

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented

### Additional Inclusion Criteria (Select if applicable)

- For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 4 months after stopping treatment

---

Prepared: December 2024. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)

---